Source: CentralCharts

Press Release: Calliditas Therapeutics : Calliditas Therapeutics: Interim Report Q2, 2019

This second quarter of 2019 was very busy and exciting as we concluded a USD 121 million (SEK 1.1 billion) outlicensing deal of Nefecon for Greater China and Singapore. Alongside this, our recruitment efforts for the NefIgArd study have been ongoing and we have seen significant progress across all continents.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Renee Aguiar-Lucander's photo - CEO of Calliditas


Renee Aguiar-Lucander

CEO Approval Rating


Calliditas is a pharmaceutical company that develops and commercializes therapeutics for the treatment of inflammatory kidney diseases. Read more